MediLink Therapeutics

Next-generation ADC therapies for cancer

Suzhou, China · Founded 2020 · $120.0M raised

Headquarters
Suzhou
Employees
51–200
Founded
2020
Business Model
B2B
Total Funding
$120.0M
Last Round
$70.0M Series BMar 2022
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

MediLink Therapeutics, founded July 8, 2020 in Suzhou, China, is an innovative drug development company specializing in antibody-drug conjugates (ADC) and related technologies. The company's proprietary TMALIN® (Tumor Microenvironment Activable Linker-payload) platform enables next-generation ADC therapeutics that combine the targeting precision of antibodies with the cytotoxic power of small molecules. MediLink has established subsidiaries in Shanghai, Boston, Hong Kong, and Singapore. Key partnerships include worldwide collaboration and license agreements with Roche and BioNTech. The company completed a $70M Series B in 2022 and its lead asset YL201 has received FDA Breakthrough Therapy Designation and Orphan Drug Designation.

Summary

MediLink Therapeutics is an Oncology company based in Suzhou, China, founded in 2020. It has raised $120.0M in total across 2 rounds, most recently a $70.0M Series B round in Mar 2022.

Tech & App Stack

Funding History

Series BSeries BMar 2022
$70.0M

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
Arcus BiosciencesIPO

Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...

Hayward, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$544.0MJan 2024
Pathos

Pathos uses multimodal oncology data and AI to simulate clinical trials, identify responsive pati...

Chicago, United States51–200Artificial Intelligence, Biotech
Series DTotal funding$467.0MMay 2025
ImmunomedicsAcquired

Biotechnology company focused on the development of antibody-drug conjugates for the treatment of...

Morris Plains, United States201–500Biotech, Oncology
Private EquityTotal funding$459.0MMay 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

MediLink Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/medilink-therapeutics"><img src="https://indexed.vc/api/badge/company/medilink-therapeutics" alt="MediLink Therapeutics on Indexed.vc" width="260" height="76" /></a>